The anti-thrombotic injection Yangzijiang, which jumped 150%, snapped up the first review.

Pharmaceutical Network July 16th, July 15, Yangzijiang submitted the sulphate hepatitis sodium injection consistency evaluation supplement application was accepted by CDE, acceptance number CYHB2050415.
-meter net data show that in 2019, China's public medical institutions terminal sul-sodium pedagogin injection sales of 126 million yuan, an increase of 150.67 percent year-on-year.
sulphate sodium is a synthetic specific activation Xa factor inhibitor, clinically used for major orthopaedic surgery in lower limbs such as hip fractures, major knee surgery or hip replacement, to prevent the occurrence of venous thromboembolism.
developed by GlaxoSmithKline and sold to Aspen.
: 2015-2019 China's public medical institutions terminal sul-sodium pedior injection sales (units: 10,000 yuan) at present, there are 2 generic pharmaceutical enterprises and a importenterprise has Sulphate hepatitis sodium injection production approval, Hengrui Pharmaceuticals in May 2018 won the first imitation of the product. According to data from
-Minnet.
table: Sulda hepatitis sodium injection consistency evaluation declaration status Sulda hepatic sodium injection has not yet been evaluated by enterprises, Jilin Jinsheng Pharmaceutical, Nanjing Jianyou Biochemical Pharmaceutical, Zhaoke Pharmaceuticals (Hefei) 3 pharmaceutical companies to copy 4 categories of production, Yangzijiang Pharmaceuticals, Jiangsu Hengrui Pharmaceutical 2 pharmaceutical companies submitted a consistency evaluation supplementapplication application, who will take the lead in the line? We'll see! Source: Minnet database, CDE official website note: statistics as of July 15, if there are omissions, welcome to point!